David A. Siegel Intra Cellular Therapies, Inc. Transaction History

Two Sigma Advisers, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$38.74 - $62.09 $444,231 - $711,986	-11,467 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$35.2 - $53.42 $403,638 - $612,567	11,467 New	11,467 $600,000
Q2 2020 Aug 14, 2020	SELL	$14.35 - $26.64 $178,901 - $332,120	-12,467 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$12.31 - $33.12 $129,255 - $347,760	-10,500 Reduced 45.72%	12,467 $192,000
Q4 2019 Feb 14, 2020	SELL	$7.26 - $38.49 $840,708 - $4.46 Million	-115,800 Reduced 83.45%	22,967 $788,000

Q3 2019 Nov 14, 2019	SELL	$7.47 - $14.03 $195,714 - $367,586	-26,200 Reduced 15.88%	138,767 $1.04 Million
Q2 2019 Aug 14, 2019	BUY	$10.65 - $14.29 $416,415 - $558,739	39,100 Added 31.06%	164,967 $2.14 Million
Q1 2019 May 15, 2019	BUY	$10.9 - $14.09 $1.06 Million - $1.38 Million	97,600 Added 345.28%	125,867 $1.53 Million
Q4 2018 Feb 14, 2019	BUY	$10.36 - $20.96 $292,846 - $592,476	28,267 New	28,267 $322,000

381

77.7M

1.7M

1.13M

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $6.47B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.